Cargando…

MCU Inhibitor Ruthenium Red Alleviates the Osteoclastogenesis and Ovariectomized Osteoporosis via Suppressing RANKL-Induced ROS Production and NFATc1 Activation through P38 MAPK Signaling Pathway

Osteoporosis is a disorder of bone metabolism that is extremely common in elderly patients as well as in postmenopausal women. The main manifestation is that the bone resorption capacity is greater than the bone formation capacity, which eventually leads to a decrease in bone mass, increasing the ri...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yuxin, Li, Xiang, Zhou, Shengji, Li, Jiarui, Zhu, Yi, Wang, Quan, Zhao, Fengchao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9489416/ https://www.ncbi.nlm.nih.gov/pubmed/36148414 http://dx.doi.org/10.1155/2022/7727006

Ejemplares similares

Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities
por: Liu, Yuhao, et al.
Publicado: (2019)

Tetrandrine inhibits RANKL-induced osteoclastogenesis by promoting the degradation of TRAIL
por: Li, Jiarui, et al.
Publicado: (2022)

Betulinic Acid Protects From Bone Loss in Ovariectomized Mice and Suppresses RANKL-Associated Osteoclastogenesis by Inhibiting the MAPK and NFATc1 Pathways
por: Wei, Jiyong, et al.
Publicado: (2020)

Adseverin mediates RANKL-induced osteoclastogenesis by regulating NFATc1
por: Song, Min-Kyoung, et al.
Publicado: (2015)

A novel BRD4 inhibitor suppresses osteoclastogenesis and ovariectomized osteoporosis by blocking RANKL-mediated MAPK and NF-κB pathways
por: Liu, Ying, et al.
Publicado: (2021)

Green tea (Camellia sinensis) aqueous extract alleviates postmenopausal osteoporosis in ovariectomized rats and prevents RANKL-induced osteoclastogenesis in vitro
por: Wu, Xin, et al.
Publicado: (2018)

Dracorhodin perchlorate inhibits osteoclastogenesis through repressing RANKL‐stimulated NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Tyloxapol inhibits RANKL-stimulated osteoclastogenesis and ovariectomized-induced bone loss by restraining NF-κB and MAPK activation
por: Guo, Wen, et al.
Publicado: (2021)

Matrine prevents bone loss in ovariectomized mice by inhibiting RANKL-induced osteoclastogenesis
por: Chen, Xiao, et al.
Publicado: (2017)

Tetrandrine Prevents Bone Loss in Ovariectomized Mice by Inhibiting RANKL-Induced Osteoclastogenesis
por: Zhong, Zeyuan, et al.
Publicado: (2020)

Cytochalasin Z11 inhibits RANKL-induced osteoclastogenesis via suppressing NFATc1 activation
por: Wang, Lu, et al.
Publicado: (2019)

Asiatic Acid Inhibits OVX-Induced Osteoporosis and Osteoclastogenesis Via Regulating RANKL-Mediated NF-κb and Nfatc1 Signaling Pathways
por: Hong, Guoju, et al.
Publicado: (2020)

C-phycocyanin attenuates RANKL-induced osteoclastogenesis and bone resorption in vitro through inhibiting ROS levels, NFATc1 and NF-κB activation
por: AlQranei, Mohammed S., et al.
Publicado: (2020)

Anemonin Attenuates RANKL-Induced Osteoclastogenesis and Ameliorates LPS-Induced Inflammatory Bone Loss in Mice via Modulation of NFATc1
por: Hou, Huanhuan, et al.
Publicado: (2020)

PRMT1 mediates RANKL-induced osteoclastogenesis and contributes to bone loss in ovariectomized mice
por: Choi, Joo-Hee, et al.
Publicado: (2018)

Astilbin prevents bone loss in ovariectomized mice through the inhibition of RANKL‐induced osteoclastogenesis
por: Jin, Haiming, et al.
Publicado: (2019)

TGFβ1 Regulates Human RANKL-Induced Osteoclastogenesis via Suppression of NFATc1 Expression
por: Tokunaga, Tadahiro, et al.
Publicado: (2020)

Sesamolin Protects Mice From Ovariectomized Bone Loss by Inhibiting Osteoclastogenesis and RANKL-Mediated NF-κB and MAPK Signaling Pathways
por: Yang, Xue, et al.
Publicado: (2021)

Icaritin ameliorates RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis
por: Huang, Jun-ming, et al.
Publicado: (2023)

Calycosin Suppresses RANKL-Mediated Osteoclastogenesis through Inhibition of MAPKs and NF-κB
por: Quan, Gui-Hua, et al.
Publicado: (2015)

MCU-Dependent mROS Generation Regulates Cell Metabolism and Cell Death Modulated by the AMPK/PGC-1α/SIRT3 Signaling Pathway
por: Wang, Yuxin, et al.
Publicado: (2021)

Disulfiram suppressed ethanol promoted RANKL-induced osteoclastogenesis in vitro and ethanol-induced osteoporosis in vivo via ALDH1A1-NFATc1 axis
por: Jia, Yewei, et al.
Publicado: (2019)

Peiminine Suppresses RANKL-Induced Osteoclastogenesis by Inhibiting the NFATc1, ERK, and NF-κB Signaling Pathways
por: Zhu, Mengbo, et al.
Publicado: (2021)

Nitazoxanide, an Antiprotozoal Drug, Reduces Bone Loss in Ovariectomized Mice by Inhibition of RANKL-Induced Osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2021)

The Roles of ROS Generation in RANKL-Induced Osteoclastogenesis: Suppressive Effects of Febuxostat
por: Ashtar, Mohannad, et al.
Publicado: (2020)

Water extract of Cnidii Rhizoma suppresses RANKL-induced osteoclastogenesis in RAW 264.7 cell by inhibiting NFATc1/c-Fos signaling and prevents ovariectomized bone loss in SD-rat
por: Lee, Ka-Yeon, et al.
Publicado: (2019)

12-Deoxyphorbol-13-Hexadecanoate Abrogates OVX-Induced Bone Loss in Mice and Osteoclastogenesis via Inhibiting ROS Level and Regulating RANKL-Mediated NFATc1 Activation
por: He, Qi, et al.
Publicado: (2022)

Melatonin Attenuates RANKL-Induced Osteoclastogenesis via Inhibition of Atp6v0d2 and DC-STAMP through MAPK and NFATc1 Signaling Pathways
por: Kim, Seong-Sik, et al.
Publicado: (2022)

STIM1 controls calcineurin/Akt/mTOR/NFATC2-mediated osteoclastogenesis induced by RANKL/M-CSF
por: Huang, Yanjiao, et al.
Publicado: (2020)

Maackiain dampens osteoclastogenesis via attenuating RANKL‐stimulated NF‐κB signalling pathway and NFATc1 activity
por: Liu, Yuhao, et al.
Publicado: (2020)

Corrigendum: Nitazoxanide, an antiprotozoal drug, reduces bone loss in ovariectomized mice by inhibition of RANKL-induced osteoclastogenesis
por: Li, Chang-hong, et al.
Publicado: (2023)

Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression
por: Lin, Wei, et al.
Publicado: (2021)

Ginsenoside Rg2 inhibits osteoclastogenesis by downregulating the NFATc1, c-Fos, and MAPK pathways
por: Lee, Sung-Hoon, et al.
Publicado: (2023)

Madecassoside inhibits estrogen deficiency‐induced osteoporosis by suppressing RANKL‐induced osteoclastogenesis
por: Wang, Qingqing, et al.
Publicado: (2018)

KMUP-1 Suppresses RANKL-Induced Osteoclastogenesis and Prevents Ovariectomy-Induced Bone Loss: Roles of MAPKs, Akt, NF-κB and Calcium/Calcineurin/NFATc1 Pathways
por: Liou, Shu-Fen, et al.
Publicado: (2013)

Angelica sinensis extract inhibits RANKL-mediated osteoclastogenesis by down-regulated the expression of NFATc1 in mouse bone marrow cells
por: Kong, Lingbo, et al.
Publicado: (2014)

Agelasine D Suppresses RANKL-Induced Osteoclastogenesis via Down-Regulation of c-Fos, NFATc1 and NF-κB
por: Kang, Moo Rim, et al.
Publicado: (2014)

The Molecular Mechanisms Study of Engeletin Suppresses RANKL-Induced Osteoclastogenesis and Inhibits Ovariectomized Murine Model Bone Loss
por: Feng, Mingzhe, et al.
Publicado: (2023)

Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL
por: Jang, Yuria, et al.
Publicado: (2021)

Inhibitory Effects of Rhaponticin on Osteoclast Formation and Resorption by Targeting RANKL-Induced NFATc1 and ROS Activity
por: He, Jianbo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p9r9c0nu1ncpj01v4ir767k216